From Wikipedia, the free encyclopedia
Jump to: navigation, search
Efonidipine structure.svg
Clinical data
Trade names Landel (ランデル)
AHFS/Drugs.com International Drug Names
Routes of
ATC code
  • none
Legal status
Legal status
  • In general: ℞ (Prescription only)
CAS Number
PubChem CID
Chemical and physical data
Formula C34H38N3O7P
Molar mass 631.65 g/mol
3D model (Jmol)
 NYesY (what is this?)  (verify)

Efonidipine (INN) is a dihydropyridine calcium channel blocker marketed by Shionogi & Co. of Japan. It was launched in 1995, under the brand name Landel (ランデル). The drug blocks both T-type and L-type calcium channels.[1]

It has also been studied in atherosclerosis[2] and acute renal failure.[3]


  1. ^ Tanaka H, Shigenobu K (2002). "Efonidipine hydrochloride: a dual blocker of L- and T-type Ca2+ channels". Cardiovasc. Drug Rev. 20 (1): 81–92. PMID 12070536. 
  2. ^ Toyoda K, Kitahara M, Yamashita T, et al. (May 1994). "[Effect of efonidipine hydrochloride (NZ-105), a new dihydropyridine calcium antagonist, on the experimental atherosclerosis in cholesterol-fed rabbits]". Nippon Yakurigaku Zasshi (in Japanese). 103 (5): 231–9. PMID 8188119. 
  3. ^ Shudo C, Masuda Y, Sugita H, Tanaka S, Tomita K (November 1994). "Effects of efonidipine hydrochloride (NZ-105), a new calcium antagonist, against acute renal failure in rats". Gen. Pharmacol. 25 (7): 1451–8. PMID 7896060.